There is one clinical trial.
COVID-19 is impacting on health systems in Brazil and worldwide. Reducing the risk of clinical deterioration and prolonged disease duration in hospitalized patients with COVID-19 may alleviate the burden caused by the pandemic. Melatonin (N-acetyl-5-methoxytryptamine) has demonstrated antiapoptotic, antioxidative, and anti-inflammatory roles and has been suggested as a potential protector against organ injuries and even mediate lower mortality rates after polymicrobial sepsis in animal models. Melatonin agonists may modulate protective effects against acute lung injury and play a clinical role in individuals with SARS-CoV-2 infection. The investigators proposed a clinical trial testing the effects of ramelteon 8mg in hospitalized patients with COVID-19.
Description: Defined as a National Early Warning Score 2 (NEWS2) of 0 maintained for 24 hours [Time Frame: Assessed daily (enrollment is day 0)] The NEWS consists of a simple aggregate scoring system based on physiological measurements, regularly registered in inpatient settings, including six parameters: respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new confusion, and temperature.Measure: Time to resolution of symptoms [National Early Warning Score 2 (NEWS2) of 0] Time: enrollment is day 0
Description: Critical COVID-19 illness as a composite of admission to the intensive care unit (ICU), invasive ventilation, or deathMeasure: Clinical worsening to critical COVID-19 illness Time: until Day 30
Description: Measured by duration of use of supplemental oxygen (if applicable)Measure: Duration of supplemental oxygen therapy Time: until day 14
Description: Measured by duration of use of mechanical ventilationMeasure: Duration of mechanical ventilation (if applicable) Time: until day 30
Description: Measured by duration of hospitalizationMeasure: Duration of hospitalisation Time: until day 30
Description: Presence or absence of SARS-CoV-2 Viral RNA in nasopharyngeal swab or lower respiratory secretionsMeasure: Proportion of participants with virologic clearance in nasopharyngeal swab RT-PCR Time: Day 14
Description: Reduction of C-reactive protein levels > 50% in comparison with PCR levels at the admissionMeasure: C-reactive protein (CRP) level's reduction Time: Days 3, 5 and 8
Description: Incidence of new onset lymphopenia during hospitalization measured by blood drawMeasure: Incidence of New Onset Lymphopenia Time: Through study completion, average of 15 days
Description: Reduction of mean direct bilirubin levels in comparison with levels at the admissionMeasure: Direct bilirubin level's reduction Time: Measured in study Days 3, 5, and 8
Description: Differences in number of patients in study arms who experienced side effectsMeasure: Side Effects Time: until day 14
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports